Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Annexin Pharmaceuticals

13.10 SEK-2.96 %9.9. klo 18.29
Less than 1K followers

ANNX

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-2.96 %
+3.56 %
+2.29 %
-8.29 %
-32.84 %
-52.51 %
-67.89 %
-86.27 %
-95.84 %

Annexin Pharmaceuticals is a biotechnology company developing the drug candidate ANXV, based on the protein Annexin A5, for the treatment of diseases such as vascular damage, inflammation and certain cancers. The company's partners are healthcare providers and biopharmaceutical companies and the business is aimed at global markets through research and licensing collaborations. The company was founded in 2014 and is headquartered in Stockholm, Sweden.

Read more
Market cap
114.21M SEK
Turnover
65.51K SEK
Revenue
EBIT %
P/E
Dividend yield-%
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Press releases
ShowingAll content types

Financial calendar
22.10.
2026

Interim report Q3'26

11.2.
2027

Annual report '26

Press release25.08.2026 klo 18.35

Redeye: Annexin (Q2 Review): Further data expected in H2

Annexin Pharmaceuticals
Press release21.08.2026 klo 09.00

Annexin advances the NEXUS study to include patients who received an anti-VEGF injection

Annexin Pharmaceuticals
Press release20.08.2026 klo 09.30

Annexin Pharmaceuticals receives the International Nonproprietary Name (INN) vanexin for the drug candidate ANXV

Annexin Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release21.07.2026 klo 09.30

Annexin updates on nine patients treated in NEXUS study

Annexin Pharmaceuticals
Regulatory press release03.07.2026 klo 14.15

Annexin's rights issue 98 percent subscribed

Annexin Pharmaceuticals
Press release23.06.2026 klo 09.30

Annexin updates on continuous promising data from the NEXUS study – demonstrating improvement of retinal perfusion in both DR and RVO

Annexin Pharmaceuticals
Regulatory press release15.06.2026 klo 09.30

The subscription period in Annexin Pharmaceuticals’ rights issue begins today

Annexin Pharmaceuticals
Regulatory press release10.06.2026 klo 09.30

Annexin Pharmaceuticals publishes Information document in connection with forthcoming rights issue

Annexin Pharmaceuticals
Press release05.06.2026 klo 09.30

Annexin Pharmaceuticals to present at Aktiedagarna in Stockholm on June 10

Annexin Pharmaceuticals
Regulatory press release03.06.2026 klo 23.50

Annexin resolves a rights issue of approximately SEK 20 million, secured to approximately 60 percent, with an overallotment option of up to approximately SEK 5 million

Annexin Pharmaceuticals
Press release21.05.2026 klo 09.30

Annexin investigates a three-day ANXV treatment regimen in patients with RVO

Annexin Pharmaceuticals
Press release11.05.2026 klo 09.30

Annexin receives clinical trial approval in Germany, widening patient recruitment in the NEXUS study

Annexin Pharmaceuticals
Press release24.04.2026 klo 10.40

Redeye: Annexin Pharmaceuticals (Q1 review): Study on track

Annexin Pharmaceuticals
Press release22.04.2026 klo 09.30

Annexin accelerates patient recruitment – five patients treated

Annexin Pharmaceuticals
Regulatory press release13.04.2026 klo 14.29

Annexin secures financing through bridge loan facility and plans a rights issue of approximately SEK 20 million during the summer of 2026

Annexin Pharmaceuticals
Press release06.02.2026 klo 16.17

Redeye: Annexin Pharmaceuticals (Q4 review): Phase II study away, with positive initial results

Annexin Pharmaceuticals
Regulatory press release04.02.2026 klo 15.36

Favourable findings in Annexin’s ongoing Phase 2a study in Diabetic Retinopathy and Retinal Vein Occlusion

Annexin Pharmaceuticals
Regulatory press release29.01.2026 klo 09.30

Annexin engages Pareto Securities as liquidity provider

Annexin Pharmaceuticals
Press release19.12.2025 klo 11.25

BioStock: Annexin has laid the foundation for continued clinical development

Annexin Pharmaceuticals
Press release18.12.2025 klo 13.30

Interview and webinar published on Annexin's ongoing Phase 2a study in diabetic retinopathy and retinal vein occlusion

Annexin Pharmaceuticals